Last reviewed · How we verify
PF-06741086 (pf-06741086)
PF-06741086, marketed by Pfizer Inc., holds a position in the pharmaceutical market with its key composition patent set to expire in 2028. The drug's primary strength lies in its current marketed status, providing a steady revenue stream for Pfizer. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | pf-06741086 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors (PHASE3)
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B (PHASE3)
- A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. (PHASE1)
- Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PHASE3)
- Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia (PHASE1)
- A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device (PHASE1)
- PF-06741086 Long-term Treatment in Severe Hemophilia (PHASE2)
- PF-06741086 Multiple Dose Study in Severe Hemophilia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06741086 CI brief — competitive landscape report
- PF-06741086 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI